Clinical Trials
6 trialsNCT07169617 2026-06-03
Testing the SurVaxM Vaccine for Lung Cancer Prevention
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT03786783 2026-06-02
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01134614 2026-05-29
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02339571 2026-05-29
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT06202066 2026-05-28
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT02334865 2026-05-15
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Roswell Park Cancer Institute
Phase 1 Active not recruiting